Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696022 | 0.88 | ALDH1A1 (0.38) | TLR7ALDH1A1GAAHTTNPSR1 | |
| SCHEMBL6704175 | 0.80 | KDM4E (0.36) | SMN1; SMN2ALDH1A1GAAHRH1HTR6 | |
| SCHEMBL6702935 | 0.79 | TLR7 (0.61) | TLR7 | |
| SCHEMBL6700118 | 0.71 | TLR7 (0.74) | TLR7 | |
| SCHEMBL7107891 | 0.70 | KDM4E (0.36) | SMN1; SMN2ALDH1A1GAAHTTNPSR1 | |
| SCHEMBL6106117 | 0.70 | TLR7 (0.63) | TLR7 | |
| SCHEMBL7106797 | 0.67 | HPGD (0.40) | SMN1; SMN2ALDH1A1GAAHTTNPSR1 | |
| SCHEMBL6105787 | 0.67 | SMN1; SMN2 (0.45) | TLR7SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL27581442 | 0.67 | CYP3A4 (0.43) | HRH1 | |
| SCHEMBL483652 | 0.66 | TLR7 (0.57) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072858-A1 | Heterocyclic ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-15 | — | — | US | disclosed |
| US-6664260-B2 | Viricides; anticarcinogneic agents; induction cytokine biosynthesis | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | disclosed |
| EP-1339715-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | disclosed |
| WO-2002046193-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | IFNG, IL2, IRF3 | TLR7 35/4885SMN1; SMN2 4312/4885ALDH1A1 2486/4885 |
| US-20040072858-A1 | Heterocyclic ether substituted imidazoquinolines | IFNG, IL2, IRF3 | TLR7 35/4885SMN1; SMN2 4312/4885ALDH1A1 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.